Table 2.
Polyunsaturated free fatty acids (ω-3 series and arachidonic acid) in the DHA-based multivitamin treatment and placebo group.
| Parameters | DHA-based multivitamin group (n = 27) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline evaluation (T0) | Follow-up (T1) | |||||||
| Mean ± SD | Median | Interval (Min-Max) | P (vs. Placebo arm T0) | Mean ± SD | Median | Interval (Min-Max) | P (vs. DHA arm T0) | |
| ω-3 fatty acids (nM) | ||||||||
| ALA | 3338.0 ± 1759.7 | 3245.9 | 731.7–8678.2 | 0.11 | 5049.9 ± 1268.0 | 4876.2 | 2793.3–8628.2 | 0.00 |
| EPA | 713.6 ± 353.0 | 668.0 | 212.4–1623.5 | 0.34 | 663.4 ± 430.1 | 496.4 | 221.2–2005.8 | 0.33 |
| DHA | 4524.4 ± 2176.0 | 4631.3 | 1808.1–12706.9 | 0.09 | 6727.8 ± 3527.8 | 6167.5 | 2651.3–15879.3 | 0.01 |
| Arachidonic acid and metabolites ( nM ) | ||||||||
| AA | 11865.0 ± 3301.7 | 12338.9 | 6267.8–17507.5 | 0.05 | 9124.6 ± 2599.6 | 8841.9 | 5534.1–16580.1 | 0.00 |
| 20-COOH-AA | 9.9 ± 6.4 | 9.0 | 1.4–30.5 | 0.03 | 10.7 ± 6.7 | 10.5 | 2.1–30.8 | 0.34 |
| 20-COOH-AA/AA (x 1000) | 0.9 ± 0.8 | 0.7 | 0.1–4.0 | 0.02 | 1.2 ± 0.8 | 1.0 | 0.2–3.1 | 0.10 |
| 20-HETE | 18.1 ± 6.9 | 18.3 | 7.5–31.7 | 0.49 | 12.3 ± 3.8 | 11.8 | 5.1–23.7 | 0.00 |
| 20-HETE/AA (x 1000) | 1.7 ± 0.9 | 1.5 | 0.7–4.0 | 0.15 | 1.4 ± 0.6 | 1.3 | 0.6–2.8 | 0.14 |
| AA / EPA | 19.8 ± 9.0 | 18.8 | 6.0–44.6 | 0.25 | 17.7 ± 8.5 | 17.2 | 6.3–39.8 | 0.20 |
| AA / DHA | 2.9 ± 1.0 | 2.6 | 1.3–5.0 | 0.00 | 1.6 ± 0.6 | 1.5 | 0.7–2.8 | 0.00 |
| Parameters | Placebo group (n = 15) | |||||||
| Baseline evaluation (T0) | Follow-up (T1) | |||||||
| Mean ± SD | Median | Interval (Min-Max) | Mean ± SD | Median | Interval (Min-Max) | P (vs. Placebo arm T0) | ||
| ω-3 fatty acids (nM) | ||||||||
| ALA | 4130.3 ± 1822.9 | 3426.0 | 2563.0–8080.5 | 4380.3 ± 1764.6 | 3975.2 | 2404.0–7785.3 | 0.37 | |
| EPA | 659.5 ± 391.2 | 529.9 | 169.7–1343.7 | 519.2 ± 200.2 | 510.0 | 286.8–824.9 | 0.14 | |
| DHA | 5537.0 ± 1890.5 | 5490.0 | 1743.9–8920.3 | 4885.4 ± 1556.5 | 4358.3 | 3089.1–7728.4 | 0.18 | |
| Arachidonic acid and metabolites ( nM ) | ||||||||
| AA | 9911.9 ± 3523.5 | 9593.8 | 2997.4–15959.3 | 9632.5 ± 3214.6 | 9848.6 | 5543.5–16451.5 | 0.42 | |
| 20-COOH-AA | 13.9 ± 4.9 | 13.3 | 7.1–21.3 | 10.8 ± 6.4 | 8.6 | 3.6–24.8 | 0.10 | |
| 20-COOH-AA/AA (x 1000) | 1.6 ± 1.2 | 1.3 | 0.7–5.1 | 1.2 ± 0.7 | 1.0 | 0.3–2.6 | 0.12 | |
| 20-HETE | 18.0 ± 8.2 | 17.3 | 6.6–31.8 | 13.7 ± 6.1 | 12.5 | 6.6–24.7 | 0.08 | |
| 20-HETE/AA (x 1000) | 2.0 ± 1.1 | 2.0 | 0.7–4.1 | 1.5 ± 0.6 | 1.3 | 0.6–3.0 | 0.07 | |
| AA/EPA | 17.9 ± 6.6 | 17.9 | 9.5–28.4 | 19.7 ± 5.3 | 20.4 | 9.9–29.6 | 0.23 | |
| AA/DHA | 1.8 ± 0.3 | 1.8 | 1.3–2.3 | 2.0 ± 0.3 | 2.0 | 1.6–2.7 | 0.07 | |
Significant differences were as P values in bold (≤0.05).